Dako enters new collaboration on targeted therapies for non-small cell lung cancer

22-Aug-2007

Dako has entered into collaboration with Genentech, OSI and Roche for the clinical development and application for a Premarket Approval Supplement (sPMA) and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the assessment of non-small cell lung cancer (NSCLC) patients considered for treatment with Tarceva® (erlotinib).

Dako possesses substantial technical knowledge regarding the utility of immunochemistry for use in characterization of EGFR protein expression in tumor cells and markets the product, EGFR pharmDx(TM), to assess clinical colon cancer tissue specimens for the presence of the EGFR protein, thereby aiding the physician in choosing appropriate therapy. Genentech, OSI and Roche have access to substantial proprietary and confidential technical and scientific information regarding their product Tarceva and were seeking a capable diagnostic collaborator.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances